Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

3.69USD
4:00pm EDT
Change (% chg)

$-0.09 (-2.38%)
Prev Close
$3.78
Open
$3.77
Day's High
$3.83
Day's Low
$3.67
Volume
13,709
Avg. Vol
50,275
52-wk High
$4.68
52-wk Low
$1.66

IMMY.OQ

Chart for IMMY.OQ

About

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through... (more)

Overall

Beta: -0.01
Market Cap(Mil.): $75.85
Shares Outstanding(Mil.): 20.07
Dividend: --
Yield (%): --

Financials

  IMMY.OQ Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -1.34 -- --
ROI: -116.23 2.34 -5.89
ROE: -277.95 0.22 -5.30

BRIEF-Imprimis Pharmaceuticals announces qtrly loss per share $0.26

* Imprimis Pharmaceuticals announces first quarter 2017 financial results

May 10 2017

BRIEF-Imprimis Pharmaceuticals Q1 loss per share $0.26

* Total revenue $6.1 million in the first quarter of 2017, up 39%

May 10 2017

BRIEF-Imprimis Pharmaceuticals and Sightlife Surgical sign agreement for national launch of Serum Tears

* Imprimis Pharmaceuticals and Sightlife Surgical sign agreement for national launch of serum tears Source text for Eikon: Further company coverage:

May 02 2017

BRIEF-Imprimis Pharmaceuticals and Precision Lens sign agreement

* Imprimis Pharmaceuticals and Precision Lens sign agreement to expand Imprimis' ophthalmic portfolio market opportunity in the U.S. Midwest

Apr 18 2017

BRIEF-Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease

* Imprimis Pharmaceuticals acquires exclusive license to patented ophthalmic formulation for dry eye disease

Apr 06 2017

BRIEF-Longboard Capital Advisors reports 6.58 pct passive stake in Imprimis Pharmaceuticals

* Longboard Capital Advisors reports 6.58 percent passive stake in Imprimis Pharmaceuticals Inc as on March 21, 2017 Source text:(http://bit.ly/2mP5PVu) Further company coverage:

Mar 29 2017

BRIEF-Imprimis Pharmaceuticals enters into agreements with two accredited investors

* Agreements for a registered direct placement of 1.3 million shares of common stock at a price of $2.40 per share

Mar 22 2017

BRIEF-Peer-reviewed paper demonstrates the benefits of dropless cataract surgery

* Peer-reviewed paper demonstrates the benefits of dropless cataract surgery

Mar 20 2017

BRIEF-Imprimis Pharmaceuticals files for offering of up to 10.73 mln shares by selling stockholders

* Files for offering of up to aggregate of 10.73 million shares of co's common stock by the selling stockholders Source text for Eikon: Further company coverage:

Jan 23 2017

More From Around the Web

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $76.98 -0.82
Sanofi SA (SASY.PA) €87.75 -0.63
Bayer AG (BAYGn.DE) €116.60 -0.35
Bayer AG (BAYE.F) -- --
Roche Holding Ltd. (ROG.S) CHF267.90 +0.90
Roche Holding Ltd. (RO.S) CHF267.75 +1.00
Merck & Co., Inc. (MRK.N) $64.04 +0.26
Novartis AG (NOVN.S) CHF79.40 +0.65

Earnings vs. Estimates